2m 2m 2m 2m 2m 2m 2m
Lexicon Pharma (LXRX)
NASDAQ
$1.88-$0.01 (-0.79%)
Price as of Jun 03, 2026 7:36 PM EDT- $968.3MMarket Cap
- 199.05%1-Year Change
- BiotechnologyIndustry
Lexicon Pharma (LXRX)
$1.88-$0.01 (-0.79%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 49.8M +60.24% | 31.1M +2,481.48% | 1.2M +766.19% | 139,000 -99.42% | |
Cost of Revenue | 274,000 -55.52% | 616,000 +624.71% | 85,000 N/A | 0 -100.00% | |
Gross Profit | 49.5M +62.58% | 30.5M +2,622.52% | 1.1M +705.04% | 139,000 -99.37% | |
Sales and Marketing Expense | 37.3M -73.92% | 143.1M +25.55% | 114.0M N/A | N/A N/A | |
Research and Development Expense | -61.1M -27.65% | -84.5M +43.46% | -58.9M +11.49% | -52.8M -65.62% | |
Depreciation and Amortization Expense | 621,000 +16.29% | 534,000 -3.61% | 554,000 +29.74% | 427,000 -85.45% | |
Total Operating Expenses | 98.7M -56.74% | 228.2M +31.94% | 173.0M +71.41% | 100.9M -50.63% | |
Operating Profit | -48.9M -75.19% | -197.1M +14.77% | -171.8M +70.45% | -100.8M +110.79% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -11.6M +317.27% | -2.8M -80.89% | |
Interest Income and Expense and Net | 0 N/A | 0 +100.00% | -11.6M +317.27% | -2.8M -80.89% | |
Total Nonoperating Income and Expense | 6.9M -43.80% | 12.3M +58.99% | 7.7M +384.46% | 1.6M -42.32% | |
Income before Taxes | -48.9M -75.19% | -197.1M +14.77% | -171.8M +70.45% | -100.8M +72.02% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -50.3M -74.88% | -200.4M +13.15% | -177.1M +73.74% | -101.9M +74.04% | |
Net Income from Continuing Operations Applicable to Common | -50.3M -74.88% | -200.4M +13.15% | -177.1M +73.74% | -101.9M +74.04% | |
Basic EPS and Net Income | -0.14 -77.78% | -0.63 -21.25% | -0.80 +29.03% | -0.62 +16.98% | |
Diluted EPS and Net Income | -0.14 -77.78% | -0.63 -21.25% | -0.80 +29.03% | -0.62 +16.98% | |
Basic Weighted Average Shares | 363.1M +13.44% | 320.0M +44.73% | 221.1M +33.43% | 165.7M +49.52% | |
Diluted Weighted Average Shares | 363.1M +13.44% | 320.0M +44.73% | 221.1M N/A | N/A N/A | |
Balance Sheet | |||||
Cash and Cash Equivalents | 34.3M -48.50% | 66.7M +196.71% | 22.5M -51.53% | 46.3M -63.29% | |
Short-Term Investments | 61.9M -63.86% | 171.3M +16.09% | 147.6M +60.37% | 92.0M +253.73% | |
Cash and Cash Equivalents and Short-Term Investments | 96.2M -59.56% | 238.0M +39.95% | 170.0M +22.89% | 138.4M -9.14% | |
Total Current Assets | 101.9M -58.61% | 246.2M +39.45% | 176.5M +25.33% | 140.9M -10.69% | |
Accumulated Depreciation | 2.7M +29.77% | 2.1M -54.03% | 4.5M +13.91% | 4.0M -31.49% | |
Property and Plant and Equipment and Net | 1.9M -25.00% | 2.5M +25.01% | 2.0M -4.06% | 2.1M +602.03% | |
Total Long-Term Assets | 368,000 0.00% | 368,000 -55.56% | 828,000 -87.86% | 6.8M +453.94% | |
Total Assets | 185.0M -38.01% | 298.4M +30.07% | 229.4M +18.08% | 194.3M -4.66% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | 12.8M -56.97% | |
Total Short-Term Debt | 4.6M -90.81% | 50.0M 0.00% | 50.0M N/A | N/A N/A | |
Total Current Liabilities | 20.9M -53.88% | 45.2M +43.43% | 31.5M +36.14% | 23.2M -50.49% | |
Total Long-Term Debt | 49.4M -50.74% | 100.3M +0.79% | 99.5M N/A | 0 N/A | |
Total Long-Term Liabilities | 7.2M +3.61% | 6.9M -93.39% | 104.8M +1,831.66% | 5.4M +787.73% | |
Total Liabilities | 77.4M -49.20% | 152.5M +11.85% | 136.3M +76.64% | 77.2M +62.76% | |
Retained Earnings | -2.0B +2.56% | -2.0B +11.34% | -1.8B +11.14% | -1.6B +13.55% | |
Total Stockholders Equity | 107.5M -26.32% | 145.9M +56.75% | 93.1M -20.50% | 117.1M -25.10% | |
Total Shares Outstanding | 365.8M +0.78% | 363.0M +47.69% | 245.8M +29.90% | 189.2M +32.98% | |
Cash Flow | |||||
Cash from Operating Activities | -67.9M -62.05% | -178.8M +10.43% | -161.9M +82.21% | -88.9M -37.85% | |
Capital Expenditures | 0 -100.00% | 1.0M +119.36% | 470,000 -64.56% | 1.3M +1,424.14% | |
Cash from Investing Activities | 113.0M +834.95% | -15.4M -69.21% | -49.9M -29.73% | -71.1M -118.67% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -48.5M -120.35% | 238.3M +26.81% | 188.0M +32.17% | 142.2M +196.32% | |
Financials Ratio | |||||
Gross Margin | 99.45% +1.46% | 98.02% +5.46% | 92.94% N/A | N/A N/A | |
Operating Margin | -98.21% -84.51% | -634.20% -95.55% | -14,264.95% N/A | N/A N/A | |
Return on Assets | -20.83% -72.57% | -75.93% -9.17% | -83.60% N/A | N/A N/A | |
Return on Equity | -39.72% -76.31% | -167.66% -0.50% | -168.50% N/A | N/A N/A | |
Revenue Growth | 60.24% -97.57% | 2,481.48% +223.87% | 766.19% N/A | N/A N/A | |
Current Ratio | 4.88 -10.25% | 5.44 -2.78% | 5.60 N/A | N/A N/A | |
Cash Ratio | 1.65 +11.67% | 1.47 +106.87% | 0.71 N/A | N/A N/A | |
Debt-to-Equity Ratio | 0.50 -51.23% | 1.03 -35.87% | 1.61 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.29 -42.04% | 0.50 -22.73% | 0.65 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow